Clinical Trial Update: Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 maintenance trial evaluating OSI-906 plus erlotinib versus placebo plus erlotinib in nonprogressors of platinum-based chemotherapy in non-small cell lun…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• OSI-906 (OSI-906)
• Tarceva (erlotinib)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy | Phase 2 | Status: COMPLETED